Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

BioLineRx recently received approval in the US for the initiation of a multi-center, open-label phase IIa study on BL-8040. BioLineRx is looking to develop BL-8040 for the treatment of acute myeloid leukemia (AML) and other types of hematological cancers.

The study will evaluate the safety and efficacy of repeated escalating doses of BL-8040 in adults suffering from relapsed/refractory AML. Secondary endpoints include pharmacokinetic profile of the candidate and an efficacy evaluation.

BioLineRx expects partial results in the fourth quarter of 2013, while the final results are expected in the second half of 2014.

We remind investors that in Sep 2012, the rights to BL-8040 were in-licensed by the company from Biokine Therapeutics Ltd.

As per BioLineRx, approximately 250,000 adults worldwide are diagnosed with AML every year. In spite of efforts being made to develop therapies for AML, less than 25% of patients survive 5 years after being diagnosed with the disease.  

Currently available treatments include chemotherapy, radiation therapy and stem cell transplantation. Eisai Co., Ltd. (ESALY) and Johnson & Johnson (JNJ - Analyst Report) are together trying to develop Dacogen (decitabine) for AML.

BioLineRx, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). We remind investors that the company suffered a pipeline setback recently with disappointing interim results being reported from the phase II/III CLARITY trial of BL-1020, being developed for the treatment of schizophrenia. The interim analysis indicated that the study will not meet its primary endpoint.

Companies like UCB (UCBJF) look well-positioned in the biopharma space. UCB carries a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%